These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 2792574

  • 1. Deferoxamine therapy in high-ferritin diabetes.
    Cutler P.
    Diabetes; 1989 Oct; 38(10):1207-10. PubMed ID: 2792574
    [Abstract] [Full Text] [Related]

  • 2. Non-insulin-dependent diabetes mellitus and elevated serum ferritin level.
    Kaye TB, Guay AT, Simonson DC.
    J Diabetes Complications; 1993 Oct; 7(4):246-9. PubMed ID: 8219368
    [Abstract] [Full Text] [Related]

  • 3. No effect of deferoxamine therapy on glucose homeostasis and insulin secretion in individuals with NIDDM and elevated serum ferritin.
    Redmon JB, Pyzdrowski KL, Robertson RP.
    Diabetes; 1993 Apr; 42(4):544-9. PubMed ID: 8454104
    [Abstract] [Full Text] [Related]

  • 4. Serum ferritin levels in poorly- and well-controlled diabetes mellitus.
    Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ.
    Endocr Res; 2003 Aug; 29(3):299-306. PubMed ID: 14535631
    [Abstract] [Full Text] [Related]

  • 5. Serum ferritin level and associated factors among uncontrolled adult type II diabetic follow-up patients: comparative based cross-sectional study.
    Bayih A, Dedefo G, Kinde S, Alem M, Negesso AE, Baye A, Abreham A, Getaneh A, Akalu GT, Bayable A, Gashaw B, Tsegaye M, Gemechu G, Wolde M.
    BMC Endocr Disord; 2024 Aug 07; 24(1):144. PubMed ID: 39107753
    [Abstract] [Full Text] [Related]

  • 6. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women.
    Kim CH, Kim HK, Bae SJ, Park JY, Lee KU.
    Metabolism; 2011 Mar 07; 60(3):414-20. PubMed ID: 20423745
    [Abstract] [Full Text] [Related]

  • 7. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
    Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, Ishizawa K, Izawa-Ishizawa Y, Kawazoe K, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T.
    Am J Physiol Endocrinol Metab; 2012 Jan 01; 302(1):E77-86. PubMed ID: 21917632
    [Abstract] [Full Text] [Related]

  • 8. Relation of iron stores to oxidative stress in type 2 diabetes.
    Kundu D, Roy A, Mandal T, Bandyopadhyay U, Ghosh E, Ray D.
    Niger J Clin Pract; 2013 Jan 01; 16(1):100-3. PubMed ID: 23377481
    [Abstract] [Full Text] [Related]

  • 9. High ferritin and low transferrin saturation are associated with pre-diabetes among a national representative sample of U.S. adults.
    Cheung CL, Cheung TT, Lam KS, Cheung BM.
    Clin Nutr; 2013 Dec 01; 32(6):1055-60. PubMed ID: 23312547
    [Abstract] [Full Text] [Related]

  • 10. Increased ferritin concentrations correlate with insulin resistance in female type 2 diabetic patients.
    Yu FJ, Huang MC, Chang WT, Chung HF, Wu CY, Shin SJ, Hsu CC.
    Ann Nutr Metab; 2012 Dec 01; 61(1):32-40. PubMed ID: 22797673
    [Abstract] [Full Text] [Related]

  • 11. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.
    Amin RF, El Bendary AS, Ezzat SE, Mohamed WS.
    Diabetes Metab Syndr; 2019 Dec 01; 13(3):2226-2229. PubMed ID: 31235161
    [Abstract] [Full Text] [Related]

  • 12. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK, Verma SH.
    J Assoc Physicians India; 2016 Sep 01; 64(9):24-28. PubMed ID: 27762511
    [Abstract] [Full Text] [Related]

  • 13. Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload.
    Alnahal AA, Tahan M, Fathy A, Fathy T.
    Saudi J Kidney Dis Transpl; 2014 Jul 01; 25(4):808-13. PubMed ID: 24969192
    [Abstract] [Full Text] [Related]

  • 14. Association of Serum Ferritin Levels with Microalbuminuria, Glycemic Control and Dyslipidemia.
    Dubey K, Usman K, Chaudhary SC, Sawlani KK, Verma SK, Ali W.
    J Assoc Physicians India; 2022 Apr 01; 70(4):11-12. PubMed ID: 35443372
    [Abstract] [Full Text] [Related]

  • 15. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, Ozdemir IC.
    J Clin Endocrinol Metab; 2001 Aug 01; 86(8):3659-64. PubMed ID: 11502793
    [Abstract] [Full Text] [Related]

  • 16. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.
    Diabetes Care; 1998 May 01; 21(5):701-5. PubMed ID: 9589227
    [Abstract] [Full Text] [Related]

  • 17. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 May 01; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
    Cusi K, Cunningham GR, Comstock JP.
    Diabetes Care; 1995 Jun 01; 18(6):843-51. PubMed ID: 7555511
    [Abstract] [Full Text] [Related]

  • 19. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.